Amgen Inc. (NASDAQ:AMGN) Shares Sold by Mayflower Financial Advisors LLC

Mayflower Financial Advisors LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 6.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,843 shares of the medical research company’s stock after selling 282 shares during the period. Mayflower Financial Advisors LLC’s holdings in Amgen were worth $1,002,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Capital Performance Advisors LLP purchased a new stake in Amgen in the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at $29,000. Matrix Trust Co purchased a new stake in shares of Amgen in the 3rd quarter valued at $36,000. Livelsberger Financial Advisory acquired a new position in Amgen during the 3rd quarter worth about $56,000. Finally, Kennebec Savings Bank purchased a new position in Amgen during the 3rd quarter valued at about $57,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Down 0.9 %

Shares of NASDAQ AMGN opened at $280.30 on Wednesday. The business has a 50-day moving average price of $271.47 and a 200 day moving average price of $305.51. The stock has a market cap of $150.67 billion, a PE ratio of 35.89, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the company earned $4.96 earnings per share. Equities research analysts forecast that Amgen Inc. will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.40%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 121.90%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AMGN. Truist Financial reduced their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday, January 8th. Wells Fargo & Company decreased their price target on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research report on Friday, January 10th. William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Finally, StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.